Tirzepatide

Dual Agonist · GIP / GLP-1 Receptor Agonist

Tirzepatide is an investigational incretin peptide that targets both GIP and GLP-1 pathways and is being studied for its potential to support glycemic control, appetite regulation, and body composition.

Trusted Quality

Tirzepatide vial reference artwork — View one-page graphic ↗

Quick Facts

Dual agonist targeting GIP and GLP-1 receptors
Investigational peptide for metabolic and obesity research
Supports appetite regulation and satiety
May improve glycemic control and insulin sensitivity
May support favorable body composition changes
Extended activity supports once-weekly administration

Research Highlights

Demonstrated substantial body-weight reduction in clinical research
Improved HbA1c, fasting glucose, and insulin sensitivity
Reduced appetite and caloric intake via incretin pathways
Supports cardiometabolic markers in studied populations
Dual-pathway mechanism may provide broader efficacy than single-pathway agents

How Tirzepatide Works

GIP Agonism

Supports insulin response and adipose tissue metabolism.

GLP-1 Agonism

Promotes satiety, slows gastric emptying, and supports healthy blood-sugar regulation.

Metabolic Support

Helps support appetite control, energy balance, and body-composition goals.

Protocol Tips

Start low and titrate gradually
Stay hydrated and prioritize protein intake
Monitor appetite, GI tolerance, and energy
Pair with a structured nutrition and activity plan
Consistency is key for best results

Cycle Guidance

Typical cycle length: 12–20 weeks
Reassess goals and response before continuation
Breaks between cycles may be considered
Use as part of a broader metabolic support strategy

Ask about available vial sizes and current pricing.

Check availability →